	US 11,851,681 B2
	Cell preparation method
Kenta Yamamoto, Kyoto (JP); Tsunao Kishida, Kyoto (JP); Yoshihiro Sowa, Kyoto (JP); Toshiro Yamamoto, Kyoto (JP); and Osam Mazda, Kyoto (JP)
Assigned to KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, Kyoto (JP)
Appl. No. 15/769,595
Filed by KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, Kyoto (JP)
PCT Filed Oct. 20, 2016, PCT No. PCT/JP2016/081187 § 371(c)(1), (2) Date Sep. 17, 2018, PCT Pub. No. WO2017/069222, PCT Pub. Date Apr. 27, 2017.
Claims priority of application No. 2015-207529 (JP), filed on Oct. 21, 2015.
Prior Publication US 2019/0024054 A1, Jan. 24, 2019
Int. Cl. C12N 5/077 (2010.01); C12N 5/0775 (2010.01)

CPC C12N 5/0656 (2013.01) [C12N 5/0653 (2013.01); C12N 5/0654 (2013.01); C12N 5/0655 (2013.01); C12N 5/0658 (2013.01); C12N 5/0663 (2013.01); C12N 2501/15 (2013.01)]

1 Claim

1. A method of generating a somatic cell comprising directly converting a fibroblast or keratinocyte of a mammal to an osteoblast by culturing the fibroblast or keratinocyte in a medium containing a TGF-β pathway inhibitor without introducing a gene and without converting into a pluripotent stem cell, wherein the TGF-β pathway inhibitor is an ALK5 inhibitor II.